Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis
- PMID: 35760379
- DOI: 10.1016/j.ijid.2022.06.033
Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis
Abstract
Relying on a biomarker to diagnose or follow up the treatment of a Candida albicans meningitis would have an impact on patient management. The biomarker 1,3, β-D-glucan (BDG), developed for serum testing, shows inconsistent values when applied on cerebrospinal fluid (CSF), and its use with the current protocol on CSF samples warrants caution.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors have no competing interests to declare.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
